CBIO · Catalyst Biosciences Inc

-

Please sign in to comment on CBIO

1 Comment

Admin

4 years, 2 months ago

Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 23.8% below its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.

Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.

Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.

Finally, its free cash flow fell by 173.8% to $-22M since the same quarter in the previous year.

Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.

Industry	Biotechnology
ISIN	US14888D2080
Sector	Healthcare
Exchange	NASDAQ
CurrencyCode	USD

Beta	1.29
Market Cap	19M
PE Ratio	None
Target Price	16
Dividend Yield	None

ABOUT

Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CBIO · Catalyst Biosciences Inc

-

Catalyst Biosciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Catalyst Biosciences Inc using a moving average strategy